Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The only thing holding this back right now is lack of news. We are overdue for an update, I expect an update is coming soon. The only person whining is......well, I think we know who it is.
Did you miss the part that the shares were restricted?
Restricted
54,929,546
10/04/2019
Not to mention that their shares are also restricted, so they won't be selling them into the market anytime soon.
FFS, their compensation was in shares, not cash. Get over it.
Nice to see good sized bids moving up and .021 on the ask. RMSL
RMSL we are now overdue for news. Give us an update that we can sink our teeth into.
Maybe because there isn't one? But, if you know of a good group to run it, by all means bring them in.
All selling seems to have dried up, time for some news and to start a move back into silver. RMSL
MEDH CEO Interview with SCV:
Mark Miller, CEO of MedX Holdings, Inc., Provides Substantial Update and Outlook in an Exclusive New Interview at SmallCapVoice.comPress Release 10/22/2019
AUSTIN, Texas, Oct. 22, 2019 (GLOBE NEWSWIRE) -- SmallCapVoice.com (SCV) and MedX Holdings, Inc. (OTC Pink: MEDH) (the Company), today announced that Company CEO, Mark Miller, is featured in a new audio interview at SmallCapVoice.com.
The interview can be heard at: https://www.smallcapvoice.com/10-21-19-smallcapvoice-interview-with-medx-holdings-medh/.
Mark Miller called in to SmallCapVoice.com to provide the MEDH shareholders and the SCV listening audience with details of the recent sale of residential real estate assets, the use of funds from that transaction, details regarding the acquisition of BioHydro LLC, the new direction for the Company stemming from that acquisition, and the operational goals for the remainder of 2019.
“With the sale of our residential real estate that generated in excess of $5.5 million dollars in net profits, the Company is now funded for future growth. This move allows us to suspend our current fundraising efforts thereby eliminating the threat of dilution to our current shareholders. As stated previously, management believes that the BioHydro opportunity presents a viable avenue for exponential revenue generation,” stated Miller. “That makes this a great time to go on the record with the knowledgeable listeners at SmallCapVoice.com. We have an extremely compelling story to tell right now given the tremendous progress we have already made and the important steps that lie in front of us as we break into an enormous market opportunity in our new market.”
Follow us on Twitter @MedX_Holdings
Website: www.medxholdings.co
Safe-Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements.
Contact:
For SmallCapVoice.com:
ssmith@smallcapvoice.com
512-267-2430
SOURCE: SmallCapVoice.com
I think the float is a bit higher too, it would be nice to see it updated.
Did you miss the fact that this ran up to the .0185 area and has since come all the way back down to where it started?
It will be awesome when DeltaWave gets its patent.
Sales networks pending thanks to the successes of our Founder’s previous design, which did roughly $200M in sales.
Tom Wood
Founder & CEO
Technical expert with 17 other patents in total. Possesses 25 years’ experience as an ICU respiratory therapist at Baylor Medical Center & Parkland Memorial hospitals, also spending 2 years with the Muscular Dystrophy Association.
Tom Wood has been awarded numerous U.S. Patents. Tom is the inventor and developer of ©Nasal Aire, ©Nasal Aire II, and ©Petite Nasal Aire. He has 25 Years of experience as a respiratory therapist in ICU at Baylor Medical Center and Parkland Memorial hospitals. He dedicated two years to the Muscular Dystrophy Association and was responsible for the respiratory care of patients with Amyotrophic Lateral Sclerosis.
The designer has been awarded 18 patents, 1 pending. The designers first product, Nasal-Aire, won the 2004 Frost and Sullivan Award for most innovative medical device of the year (see article below).
The NEW Deltawave is expected to be by far the greatest achievement.
From 2004 regarding the mask that Tom Wood, our CEO, created and which had $200 million in sales:
PALO ALTO, Calif.–(BUSINESS WIRE NEWS)–
In a recent study entitled ‘Strategic Analysis of World Sleep Apnea Therapeutic Markets,’ Frost and Sullivan recognized InnoMed Technologies Inc.’s revolutionary facial interface, a product that can provide comfort to millions of people suffering from sleep apnea, with the 2004 Frost and Sullivan Award for Product Innovation. Since masks are a very important component of continuous positive airway pressure (CPAP) therapy for sleep apnea, a comfortable mask can be crucial for patient compliance. While a number of companies have focused their efforts on developing better masks, InnoMed Technologies has excelled with the development of Nasal-Aire, a truly innovative mask. It does not require any headgear and can be worn like an oxygen canula, providing highly effective therapy.
?‘The lack of patient comfort and compliance is one of the biggest reasons for the failure of CPAP therapy, however, Nasal-Aire offers multiple benefits to patients including the freedom to speak, sleep in any direction and wear eyeglasses, which makes it a facial interface of choice,’ says Frost and Sullivan industry analyst Dhiraj Ajmani. For its innovative product that can help increase patient compliance in the CPAP market, InnoMed is the recipient of the 2004 Frost and Sullivan Award for Product Innovation. The award is presented each year to the company that has demonstrated excellence in new products and technologies within its industry. The recipient company has shown innovation by launching a broad line of emerging products and technologies. InnoMed’s’ product pipeline includes other novel products such as Nasal PAP Freestyle, a compact and comfortable interface, and the Nasal-Aire Critical Care device. Frost and Sullivan expects these products to expand the already growing market for Nasal-Aire. The company came into existence three years ago and is ISO1345-1996-certified, and the Nasal-Aire II has received its CE Mark. InnoMed’s products have found good acceptance in over 40 countries. The research-driven privately owned company is continuously developing innovative products in the fields of the rapidly growing sleep apnea and critical care markets. The simple and highly innovative, patient friendly Nasal-Aire is expected to revolutionize CPAP therapy, driving revenues for InnoMed Technologies.
?About Frost and Sullivan
Founded in 1961, Frost and Sullivan is recognized as a global leader in growth consulting. Frost and Sullivan Awards are presented to companies that demonstrate excellence in the industry through diligence, commitment and innovative business strategies required to advance in the global marketplace. Frost and Sullivan rigorously analyzes specific criteria to determine award recipients in a vast variety of market industries and landscapes. For further information, visit www.frost.com.
Exactly! RMSL!
Good morning RMSL, bring on the news!
Ask him where are the 8-k's for the closing of the $5.5 million and for the acquisition.
This is the last news we got in September, read it carefully. Many things in this PR are due for an update. News is coming!
REMSleep Receives Production of the New Deltawave CPAP Interface
ORLANDO, FL, Sept. 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – REMSleep Holdings, Inc. (OTC PINK: RMSL) and its principals are pleased to announce the company has received Deltawave production and is preparing to introduce the new Deltawave CPAP interface to market. The company has completed the Deltawave instruction manual and is finishing up packaging for the Deltawave. The company is in early negotiations with potential distributors to introduce Deltawave to market.
REMSleep is also in negotiations with a CPAP machine manufacturer. REMSleep has been testing it's new CPAP machine with the new Deltawave interface. The results have been remarkable. The new REMSleep CPAP machine and the new Deltawave interface pillows mask are a perfect fit and will have a huge impact on patient compliance to treatment. We predict the new CPAP machine will be available for market by the end of 2019.
As stated previously, REMSleep is in the process of molding the women's version of Deltawave and we expect to have the women's version available by the end of October. REMSleep is also in contract with a web development company for a new website. The new website is expected to be completed mid October.
REMSleep Holdings, Inc. was founded to design and manufacture devices and products for the treatment of sleep apnea and other respiratory conditions. With over 50 years of collective experience in CPAP therapy, the REMSleep team has extensive knowledge and understanding of CPAP and the challenges of patient compliance. REMSleep Holdings, Inc. has a new patent pending, innovative sleep apnea product that will meet multiple market needs and then be able to reach and address a large percentage of the patient population who continue to struggle with CPAP compliance.
Anything under .02 is golden. Anybody buying the offering will be paying 3X more.
RMSL looking good, news must be on the horizon.
RMSL up 43%, and has hit .02 as the high so far today. Big bidders in place, bring the volume!
Short squeeze?
RMSL up 34%, ask is thin.
RMSL starting to go!
Here we go! RMSL
RMSL starting to go! Don't miss out on a potential 10-bagger!
Cash at end of last period was over half a million dollars, and then they sold their residential properties for $5.5 million. How is this not on everybody's radar? How is this not flying into silver? MEDH
If you can score shares of MEDH for under .01, you should do it. Here is why:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151782209
SS updated yesterday, no changes:
MEDH Security Details
Share Structure
Market Cap Market Cap
1,422,177
10/17/2019
Authorized Shares
1,000,000,000
10/17/2019
Outstanding Shares
146,616,216
10/17/2019
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
Not Available
Float
15,724,016
02/27/2019
That sounds promising. Peeps will be chasing soon enough. RMSL
Both must work as I got a reply as well.
That one looks better.
RMSL getting some love.
Good to hear. Very low volume take-down, not warranted at all. Too many impatient people in the market.
Good question. He is probably not too happy with the share price right now.
This needs an 8-k too:
MedX Holdings, Inc. (OTC Pink: MEDH) (the Company) is pleased to announce the acquisition of BioHydro LLC.
Oh it reversed all right.
I would think an 8-k is in order. Somebody should ask him about it on Twitter, I don't have an account so hopefully somebody else will step up and inquire about it.
Hope you brought your wallet with you today, cheap shares are all around. I picked up a few, needs whales though....or ORCA's.
I don't disagree with that at all. But, the new direction also has great potential. I think we just need more information. How much is the project going to cost? How long before it's operational? How much of a need is there for this pharma water? What are projected sales?
Seems like some people are not happy with the companies new direction. Can't believe people would sell when the company has just sold residential property for $5.5 million. The company is now infused with cash!